Surgical Release of Hand Tendons with Wrapping of the Released Tendon Using an Amniotic Membrane
NCT ID: NCT06723782
Last Updated: 2024-12-09
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE2
16 participants
INTERVENTIONAL
2024-02-15
2026-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
\- Can wrapping an amniotic membrane around a surgically released tendon help reduce recurrence of adhesions and promote recovery of hand functionality?
Participants will:
* Undergo surgical treatment (surgical release of the tendon adhesions and wrapping of the amniotic membrane around the release tendon) on Day 0.
* Visit the center for a series of tests 15 days, 6 weeks, 3 months, 6 months after the surgical intervention.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
In their epidemiological study of 5,229 flexor tendon repairs, Dy et al. determined that 6% of patients who had undergone primary repair required a second intervention, with surgical release of adhesions around the tendons in 58% of cases. In flexor tendon repairs, adhesions are particularly promoted by damage to the tendon sheath, poor junction of the two severed ends of a lacerated tendon, or ischemia of the tendon and immobilization. Regardless of the etiology, adhesions prevent the efficient gliding of the tendon within its sheath, resulting in a discrepancy between near-normal passive range of motion and limited active range of motion.
When the range of motion deficit persists despite 6 months of high-quality rehabilitation, surgical treatment is considered. Tenolysis and early mobilization are the standard treatments for symptomatic tendon adhesions in the hand. Tenolysis involves surgically releasing the adhesions formed around the tendons. Follow-up rehabilitation after tendon surgical release can help reduce adhesion formation, though it does not completely prevent their formation or recurrence after tenolysis.
In recent years, many strategies have been proposed to limit adhesion formation after tendon repair surgery in the hand, or recurrence after tenolysis. Tested physical barriers include, among others, the interposition of an amniotic membrane or a composite of hyaluronic acid and methylcellulose, local application of sodium hyaluronate or various gels derived from proteoglycans or hyaluronan, or the use of non-steroidal anti-inflammatory drugs.
However, no definitive solution has yet been found, and to date, the use of anti-adhesion barriers remains limited in routine practice.
The product developed by TBF is set in this context with the goal of offering a safe biological solution that would minimize adhesion recurrence after tenolysis and promote the recovery of hand functionality.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
AMTRIX-D
Surgical release of the tendon and wrapping of the released tendon with desiccated amniotic membrane (AMTRIX-D)
AMTRIX-D
Use of a decellularized, viro-inactivated, desiccated, and sterile allogeneic amniotic membrane graft to wrap a tendon after release of its adhesions.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
AMTRIX-D
Use of a decellularized, viro-inactivated, desiccated, and sterile allogeneic amniotic membrane graft to wrap a tendon after release of its adhesions.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Adhesion of a flexor and/or extensor tendon of the hand.
* Adhesion localized to a single finger.
* Adhesion that has been present for at least 3 months following primary repair, despite high-quality rehabilitation. Primary repair is defined as the repair of a tendon injury, fracture, crush injury of the finger, infection, etc., leading to the adhesion of the tendon to surrounding tissue.
* Patient with a total passive range of motion of the proximal and distal interphalangeal joints of at least 150°.
* Informed and consenting patient.
* Patient enrolled in a social security plan or a beneficiary of such a plan.
Exclusion Criteria
* Patient requiring tenolysis after tendon grafting for the reconstruction of a deep common flexor or after reimplantation.
* Patient with amputated hand(s).
* Patient with an untreated fracture or non-union in the affected hand.
* Patient requiring multiple surgical interventions that may be potential confounding factors, particularly those involving additional incisions.
* Patient unable to understand rehabilitation or follow the study protocol.
* Patient with a contraindication to anesthesia.
* Person deprived of liberty by judicial or administrative decision.
* Adult subject to legal protection measures or incapable of expressing consent.
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
TBF Genie Tissulaire
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Institut Chirurgical de la Main et du Membre Supérieur
Lyon, , France
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Lionel ERHARD, MD
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2023-A01189-36
Identifier Type: OTHER
Identifier Source: secondary_id
AMTRIX-Tenolyse-TBF
Identifier Type: -
Identifier Source: org_study_id